Association between valvuloarterial impedance after transcatheter aortic valve implantation and 2-year mortality in elderly patients with severe symptomatic aortic stenosis: the OCEAN-TAVI registry.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 26 09 2018
accepted: 21 12 2018
pubmed: 2 1 2019
medline: 4 12 2019
entrez: 2 1 2019
Statut: ppublish

Résumé

Pre-procedural valvuloarterial impedance (Zva) is considered as a useful predictor of mortality in patients diagnosed as having severe aortic stenosis (AS) who undergo transcatheter aortic valve implantation (TAVI). However, the prognostic significance of post-procedural Zva remains unclear. We aimed to evaluate the prognostic significance of Zva after TAVI. We retrospectively analyzed the clinical and echocardiographic data of 1004 consecutive elderly patients (median 84 years old, 27.5% men) who underwent TAVI for severe symptomatic AS. Zva was calculated after TAVI, and patients were divided into three groups based on tertile values: the high [> 3.33 (n = 335)], intermediate [2.49-3.33 (n = 334)], and low Zva groups [< 2.49 (n = 335)]. The estimated 2-year all-cause and cardiovascular mortalities using Kaplan-Meier analysis were 16.2% [95% confidence interval (CI) 11.8-20.4] and 5.9% (95% CI 3.2-8.6), respectively. There were no significant intergroup differences in each endpoint (long-rank p = 0.518 for all-cause mortality, p = 0.757 for cardiovascular mortality). Multivariable Cox regression analyzes with adjustments of patient characteristics and medications showed that the post-procedural Zva was not associated with the 2-year all-cause mortality [intermediate Zva group versus (vs.) low Zva group: adjusted hazard ratio (aHR) = 1.34, 95% CI 0.75-2.40, p = 0.316; high Zva group vs. low Zva group: aHR = 1.17, 95% CI 0.64-2.16, p = 0.613] and cardiovascular mortality (intermediate Zva group vs. low Zva group: aHR = 1.50, 95% CI 0.56-4.06, p = 0.421; high Zva group vs. low Zva group: aHR = 1.25, 95% CI 0.43-3.65, p = 0.682). Our results suggest that post-procedural Zva was not associated with 2-year all-cause or cardiovascular mortalities in patients with severe symptomatic AS who underwent TAVI.

Identifiants

pubmed: 30599060
doi: 10.1007/s00380-018-01329-2
pii: 10.1007/s00380-018-01329-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1031-1039

Références

J Am Soc Echocardiogr. 2002 Feb;15(2):167-84
pubmed: 11836492
Circulation. 2003 Aug 26;108(8):983-8
pubmed: 12912812
Circulation. 2004 Sep 14;110(11):1473-6
pubmed: 15226213
J Am Coll Cardiol. 2005 Jul 19;46(2):291-8
pubmed: 16022957
Circulation. 2007 Jun 5;115(22):2856-64
pubmed: 17533183
J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2
pubmed: 19130998
J Am Coll Cardiol. 2009 Sep 8;54(11):1003-11
pubmed: 19729117
Int J Cardiovasc Imaging. 2012 Jan;28(1):79-87
pubmed: 21222040
Eur J Echocardiogr. 2011 May;12(5):358-63
pubmed: 21555457
J Am Soc Echocardiogr. 2012 Apr;25(4):444-53
pubmed: 22244001
Eur Heart J Cardiovasc Imaging. 2012 Oct;13(10):819-26
pubmed: 22634740
J Am Soc Echocardiogr. 2013 Jul;26(7):691-8
pubmed: 23669595
J Cardiovasc Magn Reson. 2013 May 21;15:39
pubmed: 23692630
Int J Cardiol. 2015 Feb 1;180:158-64
pubmed: 25438240
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Open Heart. 2015 Jun 26;2(1):e000241
pubmed: 26196018
JACC Cardiovasc Interv. 2018 Apr 23;11(8):771-780
pubmed: 29673509

Auteurs

Fukuko Nagura (F)

Teikyo University School of Medicine, Tokyo, Japan.

Akihisa Kataoka (A)

Teikyo University School of Medicine, Tokyo, Japan. kataoaki@sd5.so-net.ne.jp.

Masahiko Hara (M)

Shimane University Graduate School of Medicine, Izumo, Japan.

Ken Kozuma (K)

Teikyo University School of Medicine, Tokyo, Japan.

Yusuke Watanabe (Y)

Teikyo University School of Medicine, Tokyo, Japan.

Makoto Nakashima (M)

Teikyo University School of Medicine, Tokyo, Japan.

Hirofumi Hioki (H)

Teikyo University School of Medicine, Tokyo, Japan.

Hideyuki Kawashima (H)

Teikyo University School of Medicine, Tokyo, Japan.

Yugo Nara (Y)

Teikyo University School of Medicine, Tokyo, Japan.

Shinichi Shirai (S)

Kokura Memorial Hospital, Kitakyushu, Japan.

Norio Tada (N)

Sendai Kousei Hospital, Sendai, Japan.

Motoharu Araki (M)

Saiseikai Yokohama-City Eastern Hospital, Yokohama, Japan.

Toru Naganuma (T)

New Tokyo Hospital, Chiba, Japan.

Futoshi Yamanaka (F)

Shonankamakura General Hospital, Kamakura, Japan.

Hiroshi Ueno (H)

Toyama University School of Medicine, Toyama, Japan.

Minoru Tabata (M)

Tokyobay Urayasuichikawa Medical Center, Chiba, Japan.

Kazuki Mizutani (K)

Osaka City University Hospital, Osaka, Japan.

Akihiro Higashimori (A)

Kishiwada Tokushukai Hospital, Kishiwada, Japan.

Kensuke Takagi (K)

Ogaki Municipal Hospital, Gifu, Japan.

Masanori Yamamoto (M)

Nagoya Heart Center, Nagoya, Japan.
Toyohashi Heart Center, Toyohashi, Japan.

Kentaro Hayashida (K)

Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH